AMP-activated protein kinase inhibits IL-6-stimulated inflammatory response in human liver cells by suppressing phosphorylation of signal transducer and activator of transcription 3 (STAT3)

[1]  Liwu Li,et al.  Activation of AMPK inhibits inflammation in MRL/lpr mouse mesangial cells , 2009, Clinical and experimental immunology.

[2]  J. Suttles,et al.  Adenosine 5′-Monophosphate-Activated Protein Kinase Promotes Macrophage Polarization to an Anti-Inflammatory Functional Phenotype1 , 2008, The Journal of Immunology.

[3]  Eijiro Watanabe,et al.  Role of hepatic STAT3 in the regulation of lipid metabolism. , 2008, The Kobe journal of medical sciences.

[4]  E. Abraham,et al.  Activation of AMPK attenuates neutrophil proinflammatory activity and decreases the severity of acute lung injury. , 2008, American journal of physiology. Lung cellular and molecular physiology.

[5]  D. Carling,et al.  The regulation of AMP-activated protein kinase by upstream kinases , 2008, International Journal of Obesity.

[6]  U. Smith,et al.  Overexpression of Il6 leads to hyperinsulinaemia, liver inflammation and reduced body weight in mice , 2008, Diabetologia.

[7]  E. Prakash,et al.  Inhibition of lipopolysaccharide‐induced inducible nitric oxide synthase and cyclooxygenase‐2 gene expression by 5‐aminoimidazole‐4‐carboxamide riboside is independent of AMP‐activated protein kinase , 2008, Journal of cellular biochemistry.

[8]  L. Leng,et al.  Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the ischaemic heart , 2008, Nature.

[9]  Y. Cho,et al.  Five‐aminoimidazole‐4‐carboxamide‐1‐β‐4‐ribofuranoside attenuates poly (I:C)‐induced airway inflammation in a murine model of asthma , 2007, Clinical and Experimental Allergy.

[10]  U. Smith,et al.  Insulin Antagonizes Interleukin-6 Signaling and Is Anti-inflammatory in 3T3-L1 Adipocytes* , 2007, Journal of Biological Chemistry.

[11]  G. Hotamisligil,et al.  Inflammation and metabolic disorders , 2006, Nature.

[12]  B. Pedersen,et al.  Interleukin-6 Regulation of AMP-Activated Protein Kinase , 2006, Diabetes.

[13]  David Carling,et al.  Tumor necrosis factor alpha-induced skeletal muscle insulin resistance involves suppression of AMP-kinase signaling. , 2006, Cell metabolism.

[14]  D. James,et al.  Interleukin-6 Increases Insulin-Stimulated Glucose Disposal in Humans and Glucose Uptake and Fatty Acid Oxidation In Vitro via AMP-Activated Protein Kinase , 2006, Diabetes.

[15]  J. Zierath,et al.  AMP-activated protein kinase signaling in metabolic regulation. , 2006, The Journal of clinical investigation.

[16]  M. Febbraio,et al.  CNTF reverses obesity-induced insulin resistance by activating skeletal muscle AMPK , 2006, Nature Medicine.

[17]  S. Akira,et al.  Role of hepatic STAT3 in brain-insulin action on hepatic glucose production. , 2006, Cell metabolism.

[18]  A. Carter,et al.  Metformin reduces C–reactive protein but not complement factor C3 in overweight patients with Type 2 diabetes mellitus , 2005, Diabetic medicine : a journal of the British Diabetic Association.

[19]  G. Sesti,et al.  C-174G polymorphism in the promoter of the interleukin-6 gene is associated with insulin resistance. , 2005, Diabetes care.

[20]  R. Heath,et al.  Ca2+/calmodulin-dependent protein kinase kinase-beta acts upstream of AMP-activated protein kinase in mammalian cells. , 2005, Cell metabolism.

[21]  K. Wellen,et al.  Inflammation, stress, and diabetes. , 2005, The Journal of clinical investigation.

[22]  B. Pedersen,et al.  AMPK activity is diminished in tissues of IL-6 knockout mice: the effect of exercise. , 2004, Biochemical and biophysical research communications.

[23]  Kohjiro Ueki,et al.  Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[24]  A. Aljada,et al.  Evidence for a potent antiinflammatory effect of rosiglitazone. , 2004, The Journal of clinical endocrinology and metabolism.

[25]  C. Kahn,et al.  Suppressor of Cytokine Signaling 1 (SOCS-1) and SOCS-3 Cause Insulin Resistance through Inhibition of Tyrosine Phosphorylation of Insulin Receptor Substrate Proteins by Discrete Mechanisms , 2004, Molecular and Cellular Biology.

[26]  I. Kang,et al.  5-Aminoimidazole-4-carboxamide riboside suppresses lipopolysaccharide-induced TNF-alpha production through inhibition of phosphatidylinositol 3-kinase/Akt activation in RAW 264.7 murine macrophages. , 2004, Biochemical and biophysical research communications.

[27]  G. Cline,et al.  Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. , 2004, Diabetes.

[28]  M. Roden,et al.  Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions? , 2004, Diabetes.

[29]  G. Hjälm,et al.  Expression profiling of the γ-subunit isoforms of AMP-activated protein kinase suggests a major role for γ3 in white skeletal muscle , 2004 .

[30]  P. Trayhurn,et al.  Regulation of haptoglobin gene expression in 3T3-L1 adipocytes by cytokines, catecholamines, and PPARgamma. , 2004, Biochemical and biophysical research communications.

[31]  D. Hardie,et al.  CBS domains form energy-sensing modules whose binding of adenosine ligands is disrupted by disease mutations. , 2004, The Journal of clinical investigation.

[32]  T. Zimmers,et al.  Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. , 2003, Diabetes.

[33]  Jérôme Boudeau,et al.  Complexes between the LKB1 tumor suppressor, STRADα/β and MO25α/β are upstream kinases in the AMP-activated protein kinase cascade , 2003, Journal of biology.

[34]  P. Heinrich,et al.  Principles of interleukin (IL)-6-type cytokine signalling and its regulation. , 2003, The Biochemical journal.

[35]  T. Zimmers,et al.  Suppressor of Cytokine Signaling-3 (SOCS-3), a Potential Mediator of Interleukin-6-dependent Insulin Resistance in Hepatocytes* , 2003, The Journal of Biological Chemistry.

[36]  M. Febbraio,et al.  Acute interleukin‐6 administration does not impair muscle glucose uptake or whole‐body glucose disposal in healthy humans , 2003, The Journal of physiology.

[37]  R. Price,et al.  Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. , 2002, Arthritis and rheumatism.

[38]  R. Mooney,et al.  Interleukin-6 induces cellular insulin resistance in hepatocytes. , 2002, Diabetes.

[39]  M. Febbraio,et al.  Muscle‐derived interleukin‐6: mechanisms for activation and possible biological roles , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[40]  J. Manson,et al.  C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. , 2001, JAMA.

[41]  P. Heinrich,et al.  Expression of suppressors of cytokine signaling during liver regeneration. , 2001, The Journal of clinical investigation.

[42]  L Wood,et al.  Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. , 2001, American journal of physiology. Endocrinology and metabolism.

[43]  P. Heinrich,et al.  SOCS3 Exerts Its Inhibitory Function on Interleukin-6 Signal Transduction through the SHP2 Recruitment Site of gp130* , 2000, The Journal of Biological Chemistry.

[44]  D. Carling,et al.  Characterization of AMP-activated protein kinase gamma-subunit isoforms and their role in AMP binding. , 2000, The Biochemical journal.

[45]  J. Peschon,et al.  Analysis of liver regeneration in mice lacking type 1 or type 2 tumor necrosis factor receptor: Requirement for type 1 but not type 2 receptor , 1998, Hepatology.

[46]  J. Oscarsson,et al.  Hormonal regulation of liver fatty acid-binding protein in vivo and in vitro: effects of growth hormone and insulin. , 1998, Endocrinology.

[47]  J. Pickup,et al.  NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X , 1997, Diabetologia.

[48]  K. Uysal,et al.  Protection from obesity-induced insulin resistance in mice lacking TNF-α function , 1997, Nature.

[49]  S. Hawley,et al.  5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? , 1995, European journal of biochemistry.

[50]  D. Hardie,et al.  5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? , 1995, European journal of biochemistry.

[51]  G. Ramadori,et al.  Interleukin 6, the third mediator of acute‐phase reaction, modulates hepatic protein synthesis in human and mouse. Comparison with interleukin 1 β and tumor necrosis factor‐α , 1988 .

[52]  Kunihiro Suzuki,et al.  Metformin Inhibits Cytokine-Induced Nuclear Factor , 2006 .

[53]  D. Carling.  AMP-activated protein kinase: balancing the scales. , 2005, Biochimie.

[54]  J. Zierath,et al.  Expression profiling of the gamma-subunit isoforms of AMP-activated protein kinase suggests a major role for gamma3 in white skeletal muscle. , 2004, American journal of physiology. Endocrinology and metabolism.

[55]  K. Uysal,et al.  Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. , 1997, Nature.

[56]  F. Bontemps,et al.  Inhibition of glycolysis by 5-amino-4-imidazolecarboxamide riboside in isolated rat hepatocytes. , 1992, The Biochemical journal.

[57]  G. Ramadori,et al.  Interleukin 6, the third mediator of acute-phase reaction, modulates hepatic protein synthesis in human and mouse. Comparison with interleukin 1 beta and tumor necrosis factor-alpha. , 1988, European journal of immunology.